Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$2.16 USD
+0.05 (2.37%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $2.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Caribou Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -102.07 | -99.42 | -66.92 | -34.31 | -23.43 |
Depreciation/Amortization & Depletion | -0.90 | 0.83 | 1.04 | 0.90 | 0.75 |
Net Change from Assets/Liabilities | -7.32 | -4.20 | 29.07 | 0.18 | -8.27 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 17.00 | 11.83 | 4.30 | 0.02 | -1.06 |
Net Cash From Operating Activities | -93.29 | -90.97 | -32.52 | -33.22 | -32.01 |
Property & Equipment | -11.61 | -6.45 | -2.12 | -0.31 | -0.88 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -56.57 | -86.19 | -173.28 | 7.67 | 28.12 |
Other Investing Activities | 0.00 | -0.60 | -1.00 | -1.00 | 0.00 |
Net Cash from Investing Activities | -68.18 | -93.25 | -176.40 | 6.36 | 27.23 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 154.30 | 2.13 | 432.40 | 0.27 | 0.22 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -0.12 | -0.11 | -0.05 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 1.15 | 1.58 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 154.30 | 2.13 | 433.43 | 1.74 | 0.17 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -7.18 | -182.08 | 224.51 | -25.12 | -4.60 |
Cash at Beginning of Period | 58.38 | 240.47 | 15.95 | 41.07 | 45.67 |
Cash at End of Period | 51.21 | 58.38 | 240.47 | 15.95 | 41.07 |
Diluted Net EPS | -1.38 | -1.64 | -2.11 | NA | NA |
Fiscal Year End for Caribou Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -78.93 | -41.23 | -102.07 | -67.57 | -57.56 |
Depreciation/Amortization & Depletion | -0.92 | -0.83 | -0.90 | -3.26 | -2.39 |
Net Change from Assets/Liabilities | 2.01 | -0.85 | -7.32 | -12.34 | 9.73 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.77 | 5.71 | 17.00 | 11.25 | 7.10 |
Net Cash From Operating Activities | -70.07 | -37.20 | -93.29 | -71.91 | -43.12 |
Property & Equipment | -3.69 | -1.45 | -11.61 | -9.34 | -4.58 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 49.47 | 25.90 | -56.57 | -27.37 | 36.35 |
Other Investing Activities | -1.63 | -1.50 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 44.16 | 22.96 | -68.18 | -36.71 | 31.77 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 12.62 | 12.49 | 154.30 | 154.34 | 19.21 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 12.62 | 12.49 | 154.30 | 154.34 | 19.21 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -13.30 | -1.76 | -7.18 | 45.72 | 7.86 |
Cash at Beginning of Period | 51.21 | 51.21 | 58.38 | 58.38 | 58.38 |
Cash at End of Period | 37.91 | 49.45 | 51.21 | 104.10 | 66.24 |
Diluted Net EPS | -0.42 | -0.46 | -0.32 | -0.12 | -0.48 |